Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 5, 2023

Primary Completion Date

September 18, 2023

Study Completion Date

November 17, 2023

Conditions

Renal Impairment

Interventions

DRUG

IBI362

2.0mg, SC, single dose

Trial Locations (1)

Aerospace Center Hospital, Beijing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT05793450 - Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment | Biotech Hunter | Biotech Hunter